<DOC>
	<DOCNO>NCT00638157</DOCNO>
	<brief_summary>multicenter , randomize , double blind study describe safety efficacy daptomycin ( 6 mg/kg q24h ) without concomitant initial gentamicin combination therapy treatment SAIE</brief_summary>
	<brief_title>Phase 4 Efficacy Safety Study Cubicin® With Without Combination Therapy S. Aureus Infective Endocarditis ( SAIE )</brief_title>
	<detailed_description>Patients randomize either follow two treatment arm : - Arm 1 : daptomycin - Arm 2 : daptomycin initial i.v . gentamicin Patients meet inclusion criterion exhibit none exclusion criterion may enrol . Intravenous drug user ( IVDU ) patient may randomize study drug begin basis two separate peripheral blood culture positive S. aureus obtain within 96 hour prior first dose study drug . The recommended minimum duration treatment daptomycin 28 day . The duration treatment gentamicin 3 day . During study treatment , regular assessment ( include weekly safety laboratory test include CPK ) perform . An End-of-Therapy ( EOT ) evaluation perform day 1-2 day completion daptomycin study drug upon early termination ( ET ) . All patient post-therapy visit Test Cure ( TOC ) /Safety perform 21-28 day follow last dose daptomycin study drug .</detailed_description>
	<mesh_term>Endocarditis</mesh_term>
	<mesh_term>Endocarditis , Bacterial</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<criteria>1 . Written inform consent obtain ; 2 . Male female ≥18 year age ; 3 . IVDU ( confirmed history drug abuse within past 3 month recent needle track mark ) ; 4 . Definite possible IE accord modify Duke Criteria ( see Appendix A ) ; [ 17 ] ; 5 . Two blood culture positive S. aureus obtain within 96 hour prior first dose study medication acquire fresh venipuncture use aseptic technique analyze local laboratory ( see Appendix B ) . 1 . Intravascular foreign material place time positive blood culture drawn ( e.g. , intracardiac pacemaker wire , percutaneous implant venous catheter , vascular graft ) , ( exception : vascular stent place &gt; 6 month permanent pacemaker wire attach via epicardial lead allow ) ; 2 . High likelihood LIE indicate : 1 . Prior diagnosis predispose leftsided valvular pathology ( e.g. , rheumatic heart disease , bicuspid aortic valve ) ; 2 . Findings screen examination leftsided valvular pathology ( e.g. , diastolic murmur aortic insufficiency ) ; 3 . Findings screen examination major systemic emboli visceral organ ( e.g . cerebral splenic infarct ) . Patients may include finding consistent microvascular phenomenon due immune complex ( e.g. , splinter hemorrhage , conjunctival petechia , Roth 's spot , Osler 's node , Janeway 's lesion , microhematuria ) . Note : Any patient enrol study subsequently find LIE may continue trial determine clinically improve Investigator . 3 . Prosthetic heart valve ; 4 . Baseline Creatinine clearance &lt; 30 mL/min ( calculate CockcroftGault equation use actual body weight ) ; 5 . Baseline CPK value 5 X upper limit normal ( ULN ) conjunction symptom myalgia baseline CPK value 10 X ULN without symptom ; 6 . Alanine aminotransferase ( ALT ) &gt; 5 X ULN ; 7 . Aspartate aminotransferase ( AST ) &gt; 5 X ULN ; 8 . Moribund clinical condition ( i.e . high likelihood death within 3 day randomization ) ; 9 . Shock hypotension ( supine systolic blood pressure &lt; 80 mm Hg ) oliguria ( urine output &lt; 20 mL/h ) unresponsive fluid pressor within 4 hour ; 10 . Known pneumonia osteomyelitis ; 11 . Polymicrobial infection bacteremia due pathogen S. aureus ; 12 . Neutropenia ( absolute neutrophil count &lt; 0.5 X 103/μL ) and/or lymphopenia ( CD4 lymphocytes &lt; 0.2X 103/μL ) ; 13 . Anticipated require nonstudy antibiotic may potentially effective S. aureus ; 14 . Prior gentamicin therapy &gt; 1 day ; 15 . Documented history significant allergy intolerance study medication ; 16 . Unlikely comply study procedure ; 17 . Pregnant nursing . All female childbearing potential pregnancy test perform local laboratory . 18 . Female childbearing potential willing practice barrier method birth control ( e.g. , condom diaphragms together spermicidal foam gel ) treatment least 28 day treatment study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Gram-positive bacterial infection</keyword>
	<keyword>Staph Aureus</keyword>
	<keyword>endocarditis</keyword>
	<keyword>bacteremia</keyword>
	<keyword>methicillin-resistant Staphylococcus aureus ( MRSA )</keyword>
</DOC>